VEGFA and Hypertension: For instance, clinical experience of the use of anti-VEGF agents employed for their antiangiogenic effects in the oncology setting has demonstrated that blockade of VEGF signaling may occasionally result in the development of hypertension, proteinuria, or more significant renal injury [3, 5].